Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Theravance Biopharma, Inc. (TBPH)  
$9.49 0.05 (0.52%) as of 4:30 Wed 5/8


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 63,980,000
Market Cap: 607.17(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $8.22 - $11.59
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 18.6
Insider 6 Months    : 18.6
Insider 3/6 Months : 37.7
Guru Rank Number :  245
Guru Rank Value     : 4.8
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 1,499,124 1,499,124 1,499,124 1,499,124
Total Buy Value $13,117,335 $13,117,335 $13,117,335 $13,117,335
Total People Bought 1 1 1 1
Total Buy Transactions 1 1 1 1
Total Shares Sold 1,254 5,114 22,963 172,089
Total Sell Value $10,922 $50,468 $231,475 $1,835,193
Total People Sold 1 2 2 4
Total Sell Transactions 1 3 11 21
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 530
  Page 15 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Gala Renee D SVP, Chief Financial Officer   •       –      –    2018-02-12 4 A $0.00 $0 D/D 9,000 216,794     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2018-02-12 4 A $0.00 $0 D/D 9,000 136,248     -
   Winningham Rick E Chief Executive Officer   •       •      –    2018-02-12 4 A $0.00 $0 D/D 28,000 894,377     -
   Hegde Sharathchandra S SVP, Research   •       –      –    2018-02-12 4 A $0.00 $0 D/D 9,000 163,960     -
   Worboys Philip D SVP, Translational Science   •       –      –    2017-11-20 4 D $28.58 $157,276 D/D (5,503) 159,129     -
   Pasqualone Frank SVP, Chief Comm Ops Officer   •       –      –    2017-11-20 4 D $28.58 $166,336 D/D (5,820) 207,360     -
   Pitzer Kenneth R SVP, Prod Strat & Comm Plng   •       –      –    2017-11-20 4 D $28.58 $143,300 D/D (5,014) 147,306     -
   Hegde Sharathchandra S SVP, Research   •       –      –    2017-11-20 4 D $28.58 $147,959 D/D (5,177) 154,960     -
   Gala Renee D SVP, Chief Financial Officer   •       –      –    2017-11-20 4 D $28.58 $193,001 D/D (6,753) 207,794     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2017-11-20 4 D $28.58 $202,318 D/D (7,079) 127,248     -
   Haumann Brett K SVP Clin Dev & Chief Med Ofc   •       –      –    2017-11-20 4 D $28.58 $224,239 D/D (7,846) 141,496     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2017-09-06 4 S $30.77 $451,350 D/D (14,670) 134,327     -
   Pasqualone Frank SVP, Chief Comm Ops Officer   •       –      –    2017-08-21 4 B $26.34 $105,359 D/D 4,000 213,180 2.74     -
   Pitzer Kenneth R SVP, Prod Strat & Comm Plng   •       –      –    2017-08-20 4 D $27.40 $137,356 D/D (5,013) 152,320     -
   Shafer Bradford J EVP, Gen. Counsel, Secretary   •       –      –    2017-08-20 4 D $27.40 $193,965 D/D (7,079) 148,997     -
   Worboys Philip D SVP, Translational Science   •       –      –    2017-08-20 4 D $27.40 $150,755 D/D (5,502) 164,632     -
   Gala Renee D SVP, Chief Financial Officer   •       –      –    2017-08-20 4 D $27.40 $185,005 D/D (6,752) 214,547     -
   Pasqualone Frank SVP, Chief Comm Ops Officer   •       –      –    2017-08-20 4 D $27.40 $159,468 D/D (5,820) 209,180     -
   Haumann Brett K SVP Clin Dev & Chief Med Ofc   •       –      –    2017-08-20 4 D $27.40 $193,554 D/D (7,064) 149,342     -
   Hegde Sharathchandra S SVP, Research   •       –      –    2017-08-20 4 D $27.40 $141,822 D/D (5,176) 160,137     -
   Whitesides George M Director   –       •      –    2017-08-11 4 B $24.69 $98,764 I/I 4,000 4,000 2.1     -
   Malkiel Burton G Director   –       •      –    2017-08-11 4 B $24.59 $368,816 I/I 15,000 15,000 2.1     -
   Malkiel Burton G Director   –       •      –    2017-08-11 4 B $24.59 $368,855 D/D 15,000 47,571 2.39     -
   Fore Henrietta Director   –       •      –    2017-08-11 4 B $23.99 $143,932 D/D 6,000 24,000 2.39     -
   Winningham Rick E Chief Executive Officer   •       •      –    2017-08-11 4 B $24.50 $245,000 D/D 10,000 866,377 2.81     -
  530 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 15 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us